Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia

Corine J. Hess, Nicole Feller, Fedor Denkers, Angèle Kelder, Pauline A. Merle, Michael Heinrich, Amy Harlow, Johannes Berkhof, Gert J. Ossenkoppele, Quinten Waisfisz, Gerrit J. Schuurhuis

    Research output: Contribution to journalArticle

    7 Citations (Scopus)

    Abstract

    Background: About 70-80 percent of patients with acute myeloid leukemia enter complete remission, but at least half of these patients who achieve remission go on to relapse. Improved treatment is likely to come from increasing the time to relapse, especially for younger patients. With the vastly increasing number of targeted therapies there is a strong need for shortterm end-points to efficiently test such therapies for further pursuance. Minimal residual disease assessment may offer such an end-point since it is a strong independent prognostic factor. As proof of principle we examined this concept for FLT3-ITD status at diagnosis. Design and Methods: We determined FLT3-ITD status in bone marrow samples from 196 patients with newly diagnosed acute myeloid leukemia. The frequencies of residual leukemic cells of these 196 patients were assessed in 267 follow-up bone marrow samples using immunophenotypic assessment of minimal residual disease. Results: The median frequency of residual leukemic cells after the first cycle of chemotherapy was 8.5-fold higher in patients with FLT3-ITD than in those with wild type FLT3. Such a difference translates into differences in survival, even if other potentially outcome-modulating mutations, such as NPM1, KIT, NRAS, KRAS, FLT3-exon 20 and PTPN11 are included in the analysis. Conclusions: This study shows that it could be possible to study the efficacy of FLT3 inhibitors using the level of minimal residual disease as a short-term end-point.

    Original languageEnglish (US)
    Pages (from-to)46-53
    Number of pages8
    JournalHaematologica
    Volume94
    Issue number1
    DOIs
    StatePublished - Jan 2009

    Fingerprint

    Residual Neoplasm
    Acute Myeloid Leukemia
    Genotype
    Bone Marrow
    Recurrence
    Exons
    Therapeutics
    Drug Therapy
    Mutation
    Survival

    Keywords

    • Acute myeloid leukemia
    • FLT3
    • Minimal residual disease

    ASJC Scopus subject areas

    • Hematology

    Cite this

    Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia. / Hess, Corine J.; Feller, Nicole; Denkers, Fedor; Kelder, Angèle; Merle, Pauline A.; Heinrich, Michael; Harlow, Amy; Berkhof, Johannes; Ossenkoppele, Gert J.; Waisfisz, Quinten; Schuurhuis, Gerrit J.

    In: Haematologica, Vol. 94, No. 1, 01.2009, p. 46-53.

    Research output: Contribution to journalArticle

    Hess, CJ, Feller, N, Denkers, F, Kelder, A, Merle, PA, Heinrich, M, Harlow, A, Berkhof, J, Ossenkoppele, GJ, Waisfisz, Q & Schuurhuis, GJ 2009, 'Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia', Haematologica, vol. 94, no. 1, pp. 46-53. https://doi.org/10.3324/haematol.13110
    Hess, Corine J. ; Feller, Nicole ; Denkers, Fedor ; Kelder, Angèle ; Merle, Pauline A. ; Heinrich, Michael ; Harlow, Amy ; Berkhof, Johannes ; Ossenkoppele, Gert J. ; Waisfisz, Quinten ; Schuurhuis, Gerrit J. / Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia. In: Haematologica. 2009 ; Vol. 94, No. 1. pp. 46-53.
    @article{8f2227d36cd7445fbb5796452a5e6092,
    title = "Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia",
    abstract = "Background: About 70-80 percent of patients with acute myeloid leukemia enter complete remission, but at least half of these patients who achieve remission go on to relapse. Improved treatment is likely to come from increasing the time to relapse, especially for younger patients. With the vastly increasing number of targeted therapies there is a strong need for shortterm end-points to efficiently test such therapies for further pursuance. Minimal residual disease assessment may offer such an end-point since it is a strong independent prognostic factor. As proof of principle we examined this concept for FLT3-ITD status at diagnosis. Design and Methods: We determined FLT3-ITD status in bone marrow samples from 196 patients with newly diagnosed acute myeloid leukemia. The frequencies of residual leukemic cells of these 196 patients were assessed in 267 follow-up bone marrow samples using immunophenotypic assessment of minimal residual disease. Results: The median frequency of residual leukemic cells after the first cycle of chemotherapy was 8.5-fold higher in patients with FLT3-ITD than in those with wild type FLT3. Such a difference translates into differences in survival, even if other potentially outcome-modulating mutations, such as NPM1, KIT, NRAS, KRAS, FLT3-exon 20 and PTPN11 are included in the analysis. Conclusions: This study shows that it could be possible to study the efficacy of FLT3 inhibitors using the level of minimal residual disease as a short-term end-point.",
    keywords = "Acute myeloid leukemia, FLT3, Minimal residual disease",
    author = "Hess, {Corine J.} and Nicole Feller and Fedor Denkers and Ang{\`e}le Kelder and Merle, {Pauline A.} and Michael Heinrich and Amy Harlow and Johannes Berkhof and Ossenkoppele, {Gert J.} and Quinten Waisfisz and Schuurhuis, {Gerrit J.}",
    year = "2009",
    month = "1",
    doi = "10.3324/haematol.13110",
    language = "English (US)",
    volume = "94",
    pages = "46--53",
    journal = "Haematologica",
    issn = "0390-6078",
    publisher = "Ferrata Storti Foundation",
    number = "1",

    }

    TY - JOUR

    T1 - Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia

    AU - Hess, Corine J.

    AU - Feller, Nicole

    AU - Denkers, Fedor

    AU - Kelder, Angèle

    AU - Merle, Pauline A.

    AU - Heinrich, Michael

    AU - Harlow, Amy

    AU - Berkhof, Johannes

    AU - Ossenkoppele, Gert J.

    AU - Waisfisz, Quinten

    AU - Schuurhuis, Gerrit J.

    PY - 2009/1

    Y1 - 2009/1

    N2 - Background: About 70-80 percent of patients with acute myeloid leukemia enter complete remission, but at least half of these patients who achieve remission go on to relapse. Improved treatment is likely to come from increasing the time to relapse, especially for younger patients. With the vastly increasing number of targeted therapies there is a strong need for shortterm end-points to efficiently test such therapies for further pursuance. Minimal residual disease assessment may offer such an end-point since it is a strong independent prognostic factor. As proof of principle we examined this concept for FLT3-ITD status at diagnosis. Design and Methods: We determined FLT3-ITD status in bone marrow samples from 196 patients with newly diagnosed acute myeloid leukemia. The frequencies of residual leukemic cells of these 196 patients were assessed in 267 follow-up bone marrow samples using immunophenotypic assessment of minimal residual disease. Results: The median frequency of residual leukemic cells after the first cycle of chemotherapy was 8.5-fold higher in patients with FLT3-ITD than in those with wild type FLT3. Such a difference translates into differences in survival, even if other potentially outcome-modulating mutations, such as NPM1, KIT, NRAS, KRAS, FLT3-exon 20 and PTPN11 are included in the analysis. Conclusions: This study shows that it could be possible to study the efficacy of FLT3 inhibitors using the level of minimal residual disease as a short-term end-point.

    AB - Background: About 70-80 percent of patients with acute myeloid leukemia enter complete remission, but at least half of these patients who achieve remission go on to relapse. Improved treatment is likely to come from increasing the time to relapse, especially for younger patients. With the vastly increasing number of targeted therapies there is a strong need for shortterm end-points to efficiently test such therapies for further pursuance. Minimal residual disease assessment may offer such an end-point since it is a strong independent prognostic factor. As proof of principle we examined this concept for FLT3-ITD status at diagnosis. Design and Methods: We determined FLT3-ITD status in bone marrow samples from 196 patients with newly diagnosed acute myeloid leukemia. The frequencies of residual leukemic cells of these 196 patients were assessed in 267 follow-up bone marrow samples using immunophenotypic assessment of minimal residual disease. Results: The median frequency of residual leukemic cells after the first cycle of chemotherapy was 8.5-fold higher in patients with FLT3-ITD than in those with wild type FLT3. Such a difference translates into differences in survival, even if other potentially outcome-modulating mutations, such as NPM1, KIT, NRAS, KRAS, FLT3-exon 20 and PTPN11 are included in the analysis. Conclusions: This study shows that it could be possible to study the efficacy of FLT3 inhibitors using the level of minimal residual disease as a short-term end-point.

    KW - Acute myeloid leukemia

    KW - FLT3

    KW - Minimal residual disease

    UR - http://www.scopus.com/inward/record.url?scp=58149263359&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=58149263359&partnerID=8YFLogxK

    U2 - 10.3324/haematol.13110

    DO - 10.3324/haematol.13110

    M3 - Article

    VL - 94

    SP - 46

    EP - 53

    JO - Haematologica

    JF - Haematologica

    SN - 0390-6078

    IS - 1

    ER -